Blueprint Medicines patents expiration
1. Ayvakit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
| US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(11 years from now) | |
| US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | May 22, 2026 |
| New Chemical Entity Exclusivity (NCE) | Jan 9, 2025 |
| Orphan Drug Exclusivity (ODE) | Jan 9, 2027 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 2024-01-10
Market Authorisation Date: 09 January, 2020
Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation; Treatment of advanced systemic mastoc...
Dosage: TABLET;ORAL
More Information on Dosage
AYVAKIT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic